Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CSX-1004 by Cessation Therapeutics for Opium (Opioid) Addiction: Likelihood of Approval
CSX-1004 is under clinical development by Cessation Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData,...